Back to Search
Start Over
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies:results from EPICOVIDEHA survey
- Source :
- Pagano , L , Salmanton-garcía , J , Marchesi , F , Blennow , O , Gomes Da Silva , M , Glenthøj , A , Van Doesum , J A , Bilgin , Y M , Lopez-garcia , A , Itri , F , Nunes Rodrigues , R , Weinbergerová , B , Farina , F , Dragonetti , G , Berg Venemyr , C , Van Praet , J , Jaksic , O , Valkovic , T , Falces-romero , I , Martin-perez , S , Jiménez , M , Davila-valls , J , Schonlein , M , Ammatuna , E , Meers , S , Delia , M , Stojanoski , Z , Nordlander , A , Lahmer , T , Pinczés , L I , Buquicchio , C , Piukovics , K , Ormazabal-velez , I , Fracchiolla , N S , Samarkos , M , Mendez , G , Hernández-rivas , J , Espigado , I , Cernan , M , Petzer , V , Lamure , S , Di Blasi , R , Marques De Almeida , J , Dargenio , M , Biernat , M M , Sciumè , M , De Ramón , C , De Jonge , N A , Batinic , J , Aujayeb , A , Marchetti , M , Fouquet , G , Fernández Escalada , N , Zambrotta , G P M , Sacchi , M V , Guidetti , A , Demirken , F , Prezioso , L , Racil , Z , Nucci , M , Mladenovic , M , Lievin , R , Hanakova , M , Grafe , S K , Sili , U , Machado , M , Cattaneo , C , Adzic-vukicevic , T , Verga , L , Labrador , J , Rahimli , L , Bonanni , M , Passamonti , F , Pagliuca , A , Corradini , P , Hoenigl , M , Koehler , P , Busca , A & Cornely , O A 2022 , ' Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey ' , Blood , pp. 2773–2787 .
- Publication Year :
- 2022
-
Abstract
- Limited data have been published on the epidemiology and outcomes of breakthrough COVID-19 in patients with hematological malignancy (HM) after anti-SARS-CoV-2 vaccination. Adult HM who received at least one dose of anti-SARS-CoV-2 vaccine and diagnosed with breakthrough COVID-19 between January 2021 and March 2022 and registered in EPICOVIDEHA were included in this analysis. A total of 1548 cases were included, mainly with lymphoid malignancies (1181 cases, 76%). After viral genome sequencing in 753 cases (49%), Omicron variant was prevalent (517, 68.7%). Most of the patients received at least two vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received specific treatment for COVID-19. After 30-days follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with Omicron variant was of 7.9%, comparable to that reported for the other variants. The 30-day mortality rate was significantly lower than in the pre-vaccine era (31%). In the univariable analysis, older age (p<0.001), active HM (p<0.001), severe and critical COVID-19 (p=0.007 and p<0.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (p<0.001). In the multivariable model, older age, active disease, critical COVID-19 and at least 2-3 comorbidities were correlated with a higher mortality, whereas the administration of monoclonal antibodies, alone (p<0.001) or combined with antivirals (p=0.009), was observed protective. While mortality is significantly lower than in the pre-vaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals. EPICOVIDEHA (www.clinicaltrials.gov; National Clinical Trials identifier NCT04733729) is an international open web-based regi
Details
- Database :
- OAIster
- Journal :
- Pagano , L , Salmanton-garcía , J , Marchesi , F , Blennow , O , Gomes Da Silva , M , Glenthøj , A , Van Doesum , J A , Bilgin , Y M , Lopez-garcia , A , Itri , F , Nunes Rodrigues , R , Weinbergerová , B , Farina , F , Dragonetti , G , Berg Venemyr , C , Van Praet , J , Jaksic , O , Valkovic , T , Falces-romero , I , Martin-perez , S , Jiménez , M , Davila-valls , J , Schonlein , M , Ammatuna , E , Meers , S , Delia , M , Stojanoski , Z , Nordlander , A , Lahmer , T , Pinczés , L I , Buquicchio , C , Piukovics , K , Ormazabal-velez , I , Fracchiolla , N S , Samarkos , M , Mendez , G , Hernández-rivas , J , Espigado , I , Cernan , M , Petzer , V , Lamure , S , Di Blasi , R , Marques De Almeida , J , Dargenio , M , Biernat , M M , Sciumè , M , De Ramón , C , De Jonge , N A , Batinic , J , Aujayeb , A , Marchetti , M , Fouquet , G , Fernández Escalada , N , Zambrotta , G P M , Sacchi , M V , Guidetti , A , Demirken , F , Prezioso , L , Racil , Z , Nucci , M , Mladenovic , M , Lievin , R , Hanakova , M , Grafe , S K , Sili , U , Machado , M , Cattaneo , C , Adzic-vukicevic , T , Verga , L , Labrador , J , Rahimli , L , Bonanni , M , Passamonti , F , Pagliuca , A , Corradini , P , Hoenigl , M , Koehler , P , Busca , A & Cornely , O A 2022 , ' Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey ' , Blood , pp. 2773–2787 .
- Notes :
- application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1372661598
- Document Type :
- Electronic Resource